Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
Are you an emerging or small biotech seeking to optimize the early phase development of your small molecule or biologic drug product? Join the webinar recording, available on demand that highlights important regulatory considerations that apply across the global landscape, and help accelerate your initial clinical trials.
In this webinar, our ex-agency expert panel discussed potential early phase challenges and offered strategic solutions to avoid or overcome them.
What will you learn?
- Early-phase CMC strategies for biologics and small molecules
- Essential non-clinical considerations for first-in-human (FIH) trials
- Clinical and clinical pharmacology perspectives
Don't miss this opportunity to gain actionable insights that could advance your early phase development strategy and maximize opportunities for regulatory success.
Related Insights
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Related Insights
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025